Terms: = Lung cancer AND ATP2B3, PMCA3, 492, ENSG00000067842 AND Prognosis
43 results:
1. [Exploration of the Perturbation of PKIG in lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].
Liu Q; Li H; Li B; Ren M; Li Z; Chen Y; Zheng Z; Meng Y; Feng H
Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):523-537. PubMed ID: 37653016
[TBL] [Abstract] [Full Text] [Related]
2. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract] [Full Text] [Related]
3. Segmentectomy versus lobectomy for deep clinical T1a-bN0M0 non-small cell lung cancer.
Li Z; He Z; Xu W; Wang J; Zhu Q; Chen L; Wu W
Eur J Surg Oncol; 2023 Oct; 49(10):106946. PubMed ID: 37286427
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
[No Abstract] [Full Text] [Related]
5. Pretreatment Platelet Count is a Prognostic Marker in lung cancer: A Danish Registry-based Cohort Study.
Sandfeld-Paulsen B; Aggerholm-Pedersen N; Winther-Larsen A
Clin Lung Cancer; 2023 Mar; 24(2):175-183. PubMed ID: 36646586
[TBL] [Abstract] [Full Text] [Related]
6. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract] [Full Text] [Related]
7. Elevation of circulating TNF receptor 2 in cancer: A systematic meta-analysis for its potential as a diagnostic cancer biomarker.
Kartikasari AER; Cassar E; Razqan MAM; Szydzik C; Huertas CS; Mitchell A; Plebanski M
Front Immunol; 2022; 13():918254. PubMed ID: 36466914
[TBL] [Abstract] [Full Text] [Related]
8. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract] [Full Text] [Related]
9. [Construction of a nomogram model for predicting 2-year survival rate of small cell lung cancer based on more comprehensive variables].
Wei LJ; Hou Q; Yao NN; Liang Y; Cao X; Sun BC; Li HW; Liu JT; Xu SM; Cao J
Zhonghua Yi Xue Za Zhi; 2022 May; 102(17):1283-1289. PubMed ID: 35488697
[No Abstract] [Full Text] [Related]
10. Association of Smoking With Patient Characteristics and Outcomes in Small Cell lung Carcinoma, 2011-2018.
Tseng JS; Chiang CJ; Chen KC; Zheng ZR; Yang TY; Lee WC; Hsu KH; Huang YH; Liu TW; Hsia JY; Chang GC
JAMA Netw Open; 2022 Mar; 5(3):e224830. PubMed ID: 35353165
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of pre-treatment advanced lung cancer inflammation index in non-small cell lung cancer: a meta-analysis.
Tang Y; Ji Y; Yang M
Biomarkers; 2022 Jul; 27(5):441-447. PubMed ID: 35297277
[TBL] [Abstract] [Full Text] [Related]
12. Ultrasound-targeted microbubble destruction mediated miR-492 inhibitor suppresses the tumorigenesis in non-small cell lung cancer.
Zou W; Wang Y; Song Q; Li Q; Ren J; Liu X; Cui W
Ann Med; 2021 Dec; 53(1):2246-2255. PubMed ID: 34818961
[TBL] [Abstract] [Full Text] [Related]
13. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
Han J; Fu C; Li B
Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
[TBL] [Abstract] [Full Text] [Related]
14. Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage lung Adenocarcinoma and Their Prognostic Impacts.
Zhou J; Liu B; Li Z; Li Y; Chen X; Ma Y; Yan S; Yang X; Zhong L; Wu N
Mol Cell Proteomics; 2021; 20():100015. PubMed ID: 33508502
[TBL] [Abstract] [Full Text] [Related]
15. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract] [Full Text] [Related]
16. Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study.
Seo MS; Hwang IC; Jung J; Lee H; Choi JH; Shim JY
BMC Palliat Care; 2020 Jul; 19(1):94. PubMed ID: 32611346
[TBL] [Abstract] [Full Text] [Related]
17. Pulmonary and overall healthcare utilization after childhood and young adult thyroid cancer.
Di Giuseppe G; Zuk AM; Wasserman JD; Pole JD
Endocr Relat Cancer; 2020 Jun; 27(6):391-402. PubMed ID: 32252026
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic Value of Pretreatment Albumin to Globulin Ratio in lung cancer: A Meta-Analysis.
Li J; Wang Y; Wu Y; Li J; Che G
Nutr Cancer; 2021; 73(1):75-82. PubMed ID: 32148098
[No Abstract] [Full Text] [Related]
19. CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression.
Yin X; Xia J; Sun Y; Zhang Z
BMC Pulm Med; 2020 Feb; 20(1):40. PubMed ID: 32054470
[TBL] [Abstract] [Full Text] [Related]
20. The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
Shiina Y; Nakajima T; Yamamoto T; Tanaka K; Sakairi Y; Wada H; Suzuki H; Yoshino I
PLoS One; 2019; 14(12):e0222050. PubMed ID: 31877562
[TBL] [Abstract] [Full Text] [Related]
[Next]
